Claim Amendments

1(currently amended). A compound according to formula I, or a pharmaceutically acceptable salt thereof:



I

wherein R^a is ~~H or a~~  group;

is ~~an aryl~~ a phenyl group;

X is H, halogen, -OH, -CN, -C≡C-R^{3a}, a -C_1-C_4 alkyl group optionally substituted with from one to three halogen atoms, or a -O(C_1-C_4 alkyl) group optionally substituted with from one to three halogen atoms;

~~Q is H, halogen, a C_1-C_6 alkyl, -OH, -CN, -OCH_3, -NH_2, -NH(C_1-C_4 alkyl), -N(C_1-C_4 alkyl)(C_1-C_4 alkyl), -C(=O)NH_2, -C(=O)NH(C_1-C_4 alkyl), -C(=O)N(C_1-C_4 alkyl)(C_1-C_4 alkyl), -NHC(=O)R^{15}, or -NHS(=O)$_2R^{15}$;~~

Q is substituted at a meta position on said phenyl group and is selected from the group consisting of -C(=O)NH_2, -OH and -$NHSO_2R^{15}$;

~~R^{3a}, R^{4a}, R^{4b}, R^{4c}, R^{4d} and R^{5a} are independently~~ is H or C_1-C_6 alkyl which may be optionally substituted with one or more halogen groups~~, or R^{4a} and R^{5a}, together with the nitrogen atom to which they are bound, form a 4- to 7-membered heterocylic group which may be unsubstituted or substituted with one or more substituents selected from C_1-C_4 alkyl, -O(C_1-C_4)alkyl, -OH, =O, -$NR^{16a}R^{16b}$, halogen or -C≡C-R^{3a}~~;

~~R^{6a} is a C_1-C_6 alkyl, an aryl or a heteroaryl group wherein said alkyl, aryl or heteroaryl group is unsubstituted or substituted with one or more substituents selected from halogen, C_1-C_4 alkyl, -OH, -O(C_1-C_4 alkyl), -(C_1-C_4 alkyl)-O-(C_1-C_4 alkyl) or -$(CH_2)_n$-$NR^{21}R^{22}$;~~

~~R^{7a} and R^{7b} are independently selected from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, and aryl (wherein each of said C_1-C_6 alkyl, C_3-C_6 cycloalkyl, and aryl may independently be unsubstituted or substituted with halogen or C_1-C_4 alkyl substituents), or R^{7a} is H;~~

R^1 and R^2 are independently H, a C_1-C_8 alkyl, -$(CH_2)_t$-aryl, -$(CH_2)_t$-heteroaryl, wherein said alkyl, -$(CH_2)_t$-aryl or –$(CH_2)_t$-heteroaryl group is optionally substituted with one or more R^{16} groups, or with the carbon to which R^1 and R^2 are attached, R^1 and R^2 form a C_3-C_7 carbocyclic or 4- to 7-membered heterocyclic group, wherein said heterocyclic group comprises from one to three heteroatoms selected from the group consisting of O, S and N and said carbocyclic or heterocyclic group optionally contains a –C(=O) group or optionally contains one or more double bonds and is optionally fused to or substituted with a C_6-C_{14} aryl or a 5- to 14-membered heteroaryl group, wherein said C_3-C_7 carbocyclic or 4- to 7-membered heterocyclic group formed by R^1 and R^2 may optionally be substituted with from one to three R^{16} groups, and said optionally fused or substituted aryl or heteroaryl group may each optionally independently be substituted with from one to six R^{16} groups;

each R^{16} is independently selected from R^{17}, H, halogen, -OR^{17}, -NO_2, -CN, -C_1-C_6 alkyl, -C_3-C_8 cycloalkyl, -$C(R^4)R^{16a}R^{16b}$, aryl optionally substituted with from 1 to 3 R^4 groups, -$(CH_2)_vNR^{17}R^{18}$, -$NR^{17}C(=O)R^{18}$, -$C(=O)NR^{17}R^{18}$, -$OC(=O)R^{17}$, -$C(=O)OR^{17}$, -$C(=O)R^{17}$, -$NR^{17}C(=O)OR^{18}$, -$NR^{17}C(=O)N\ R^{18}R^{19}$, -$NR^{17}S(=O)_2R^{18}$, -$NR^{17}S(=O)_2NR^{18}R^{19}$, and -$S(=O)_2R^{17}$;

R^3 is H, F, Cl, -OH, -C_1-C_4 alkyl, -C≡N, -$NR^{17}C(=O)R^{18}$, -$C(=O)NR^{17}R^{18}$, –$O(C_1$-$C_4)$alkyl, -$(CH_2)_n$OH, -$(CH_2)_n$-C≡N, -$(CH_2)_n$-$NR^{17}C(=O)R^{18}$, -$(CH_2)_n$-$C(=O)NR^{17}R^{18}$, -$(CH_2)_n$-$O(C_1$-$C_4)$alkyl, or -$(CH_2)_n$-$NR^{16a}R^{16b}$;

R^4 is absent or is H, -C_1-C_4 alkyl, which optionally contains one or two unsaturated bonds, -OH, -$O(C_1$-$C_4)$alkyl, -$(C_1$-$C_4)$alkylOH, -$(CH_2)_n$-$NR^{16a}R^{16b}$, -$(CH_2)_n$-NHC(=O)$(C_1$-C_4 alkyl), -$(CH_2)_n$-NO_2, -$(CH_2)_n$-C≡N, -$(CH_2)_n$-$C(=O)NH_2$, -$(CH_2)_n$-$C(=O)NR^{16a}R^{16b}$;

R^5 and R^8 are independently selected from H, Cl, F, -OH, C_1-C_4 alkyl, -$O(C_1$-$C_4)$alkyl, -$C(=O)R^{20}$, -$(C_1$-C_4 alkyl)-OR^{20}, -$C(=O)OR^{20}$, -$OC(=O)R^{20}$, -$S(O)_mR^{20}$ and –$NHSO_2(C_1$-$C_4)$alkyl;

R^6, R^7, R^9, R^{10}, R^{11}, R^{12}, R^{13} and R^{14} are each independently selected from H, F, Cl, -OH, -$(C_1$-$C_4)$alkyl and -$O(C_1$-$C_4)$alkyl;

R^{15}, R^{17}, R^{18} and R^{19} are independently H, -C_1-C_4 alkyl, -$(C_2$-C_4 alkyl)-O-$(C_1$-C_4 alkyl), -$(CH_2)_v$-$NR^{21}R^{22}$, or a 4- to 7-membered heterocyclic group optionally substituted with a –C_1-C_4 alkyl;

each R^{16a} and R^{16b} is independently selected from H and C_1-C_4 alkyl; or, independently in each instance of –$C(R^4)R^{16a}R^{16b}$, R^{16a} and R^{16b} connect to form a C_3-C_7 carbocyclic ring;

R^{20} is a C_1-C_4 alkyl group, a C_3-C_7 carbocyclic or a 4- to 7-membered heterocyclic group comprising from one to three heteroatoms selected from the group consisting of O, S and N, wherein said carbocyclic and heterocyclic groups are optionally independently substituted with from one to three R^{16} groups, optionally independently contain one or more double bonds, and are optionally fused to a C_6-C_{14} aryl or a C_5-C_{14} heteroaryl group comprising from one to three heteroatoms selected from the group consisting of O, S and N, and wherein said optionally fused

aryl or heteroaryl groups can each optionally independently be substituted with from one to six R^{16} groups;

R^{21} and R^{22} are each independently H or C_1-C_6 alkyl; or, independently in each instance of $-NR^{21}R^{22}$, R^{21} and R^{22} connect to form a 4- to 7-membered heterocyclic ring comprising from one to three hetero atoms selected from O, S, and N;

j is in each instance independently an integer from 0 to 5;

m is in each instance independently an integer from 0 to 2;

n is in each instance independently an integer from 0 to 5;

v is in each instance independently an integer from 0 to 5;

or a pharmaceutically acceptable salt thereof;

with the provisos that

a) when R^8 is and n is 0, and when the carbon to which R^1, R^2 and R^4 are bound is sp^3 hybridized (i.e., "saturated"), then none of R^1, R^2 and R^4 can be a heteroatom or contain a heteroatom which is directly linked to the carbon of said  group;

b) R^{15} cannot be H when part of a $-NHS(=O)_2R^{15}$ group, R^{17} cannot be H when part of a $-S(=O)_2R^{17}$ group and R^{18} cannot be H when part of a $-NR^{17}S(=O)_2R^{18}$ group;

c) when R^8 is OCH_3 or OH,  cannot be 3-hydroxyphenyl or 3-methoxyphenyl; and

d) ~~when~~ ~~is a phenyl group, then Q and X are not both H;~~

~~e)~~ when ~~$-(CH_2)_v-$~~ is connected to N, O, or S, then v cannot be 1; and

~~f)~~  ~~cannot be 4-(6-amino-pyridin-2-yl)-phenyl~~.

2-3(cancelled).

4(currently amended). A compound according to ~~claim 2~~ claim 1 wherein X is H, F or C≡N.

5(currently amended). A compound according to ~~any of claim 2~~ claim 1, wherein R^3 is H, OH, Cl, methyl, ethyl, isopropyl, OMe, OEt, O-*i*Pr, O-allyl or O-*n*-Pr.

6(currently amended). A compound according to claim 1, wherein  ~~is a phenyl group; Q is substituted at a meta position on said phenyl group and is selected from -C(=O)NH$_2$, -OH and -NHSO$_2$R^{16};~~ R^a ~~is a~~  ~~group; and~~ R^1 and R^2 taken together with the carbon to which they are attached form a cyclobutane, cyclopentane, cyclohexane, indane-2-yl or 1,2,3,4-tetrahydronaphth-2-yl which may be unsubstituted or substituted with R^{16} groups; and wherein R^4 is H, OH, -NH(=O)-CH$_3$, –C(=O)NH$_2$, -CH$_2$OH or -OCH$_3$.

7(currently amended). A compound according to ~~claim 2~~ claim 1, wherein n is 1, 2 or 3.

8(currently amended). A compound according to ~~claim 2~~ claim 1, wherein R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13} and R^{14} are each H.

9 (cancelled).

10(currently amended). A compound according to claim 1 selected from the group consisting of

3-(3-Cyclopropylmethyl-3-aza-bicyclo[3.2.1]oct-8-yl)-phenol;

3-(3-Ethyl-8-methoxy-3-aza-bicyclo[3.2.1]oct-8-yl)-benzamide;

3-(3-Cyclopropylmethyl-8-methoxy-3-aza-bicyclo[3.2.1]oct-8-yl)-benzamide;

3-[3-(3-Cyclohexyl-propyl)-3-aza-bicyclo[3.2.1]oct-8-yl]-phenol;

3-[8-Methoxy-3-(3-methyl-butyl)-3-aza-bicyclo[3.2.1]oct-8-yl]-benzamide;

3-(8-Methoxy-3-pentyl-3-aza-bicyclo[3.2.1]oct-8-yl)-benzamide;

3-[8-Methoxy-3-(1H-pyrrol-2-ylmethyl)-3-aza-bicyclo[3.2.1]oct-8-yl]-benzamide;

3-(3-Hexyl-8-methoxy-3-aza-bicyclo[3.2.1]oct-8-yl)-benzamide;

3-[3-(2-Ethyl-butyl)-8-methoxy-3-aza-bicyclo[3.2.1]oct-8-yl]-benzamide;

2-[8-(3-Hydroxy-phenyl)-3-aza-bicyclo[3.2.1]oct-3-ylmethyl]-indan-2-ol;

3-[8-Methoxy-3-(1-methyl-1H-pyrrol-2-ylmethyl)-3-aza-bicyclo[3.2.1]oct-8-yl]-benzamide;

3-(8-Methoxy-3-thiophen-3-ylmethyl-3-aza-bicyclo[3.2.1]oct-8-yl)-benzamide;

3-(8-Methoxy-3-thiazol-2-ylmethyl-3-aza-bicyclo[3.2.1]oct-8-yl)-benzamide;

3-[3-(1-Hydroxy-cyclohexyl)-propyl]-8-(3-hydroxy-phenyl)-3-aza-bicyclo[3.2.1]octan-8-ol;

N-[3-(3-Cyclopropylmethyl-8-methoxy-3-aza-bicyclo[3.2.1]oct-8-yl)-phenyl]-methanesulfonamide;

3-(8-Methoxy-3-phenethyl-3-aza-bicyclo[3.2.1]oct-8-yl)-benzamide;

3-(2-Hydroxy-indan-2-ylmethyl)-8-(3-hydroxy-phenyl)-3-aza-bicyclo[3.2.1]octan-8-ol;

N-[3-(3-Isobutyl-8-methoxy-3-aza-bicyclo[3.2.1]oct-8-yl)-phenyl]-methanesulfonamide;

3-(8-Methoxy-3-octyl-3-aza-bicyclo[3.2.1]oct-8-yl)-benzamide;

3-{3-[3-(1-Hydroxy-cyclohexyl)-propyl]-8-methoxy-3-aza-bicyclo[3.2.1]oct-8-yl}-phenol;

3-[8-Methoxy-3-(3-phenyl-prop-2-ynyl)-3-aza-bicyclo[3.2.1]oct-8-yl]-benzamide;

3-[8-Methoxy-3-(3-phenyl-propyl)-3-aza-bicyclo[3.2.1]oct-8-yl]-benzamide;

2-[8-(3-Hydroxy-phenyl)-8-methoxy-3-aza-bicyclo[3.2.1]oct-3-ylmethyl]-indan-2-ol;

N-{3-[8-Methoxy-3-(3-methyl-butyl)-3-aza-bicyclo[3.2.1]oct-8-yl]-phenyl}-methanesulfonamide;

N-[3-(8-Methoxy-3-pentyl-3-aza-bicyclo[3.2.1]oct-8-yl)-phenyl]-methanesulfonamide;

3-[3-(1H-Indol-3-ylmethyl)-8-methoxy-3-aza-bicyclo[3.2.1]oct-8-yl]-benzamide;

3-(3-Benzofuran-2-ylmethyl-8-methoxy-3-aza-bicyclo[3.2.1]oct-8-yl)-benzamide;

3-[3-(2-Hydroxy-1,2,3,4-tetrahydro-naphthalen-2-ylmethyl)-3-aza-bicyclo[3.2.1]oct-8-yl]-benzamide;

N-{3-[3-(2-Ethyl-butyl)-8-methoxy-3-aza-bicyclo[3.2.1]oct-8-yl]-phenyl}-methanesulfonamide;

N-[3-(3-Hexyl-8-methoxy-3-aza-bicyclo[3.2.1]oct-8-yl)-phenyl]-methanesulfonamide;

3-(8-Methoxy-3-naphthalen-2-ylmethyl-3-aza-bicyclo[3.2.1]oct-8-yl)-benzamide;

3-{3-[3-(1-Hydroxy-cyclohexyl)-propyl]-8-methoxy-3-aza-bicyclo[3.2.1]oct-8-yl}-benzamide;

3-(8-Methoxy-3-quinolin-3-ylmethyl-3-aza-bicyclo[3.2.1]oct-8-yl)-benzamide;

N-[3-(8-Methoxy-3-pyridin-3-ylmethyl-3-aza-bicyclo[3.2.1]oct-8-yl)-phenyl]-methanesulfonamide;

3-[3-(4-Chloro-2-fluoro-benzyl)-8-methoxy-3-aza-bicyclo[3.2.1]oct-8-yl]-benzamide;

3-[8-Methoxy-3-(1-methyl-1H-indol-3-ylmethyl)-3-aza-bicyclo[3.2.1]oct-8-yl]-benzamide;

3-[3-(2-Hydroxy-1,2,3,4-tetrahydro-naphthalen-2-ylmethyl)-8-hydroxy-3-aza-bicyclo[3.2.1]oct-8-yl]-benzamide;

3-[3-(2-Hydroxy-indan-2-ylmethyl)-8-methoxy-3-aza-bicyclo[3.2.1]oct-8-yl]-benzamide;

N-[3-(8-Methoxy-3-thiazol-2-ylmethyl-3-aza-bicyclo[3.2.1]oct-8-yl)-phenyl]-methanesulfonamide;

3-[8-Methoxy-3-(2-phenethyloxy-ethyl)-3-aza-bicyclo[3.2.1]oct-8-yl]-benzamide;

N-[3-(3-Heptyl-8-methoxy-3-aza-bicyclo[3.2.1]oct-8-yl)-phenyl]-methanesulfonamide;

2-Methoxy-ethanesulfonic acid [3-(8-hydroxy-3-pentyl-3-aza-bicyclo[3.2.1]oct-8-yl)-phenyl]-amide;

2-Methoxy-ethanesulfonic acid {3-[8-hydroxy-3-(3-methyl-butyl)-3-aza-bicyclo[3.2.1]oct-8-yl]-phenyl}-amide;

N-[3-(8-Methoxy-3-phenethyl-3-aza-bicyclo[3.2.1]oct-8-yl)-phenyl]-methanesulfonamide;

3-[3-(4-Hydroxy-naphthalen-1-ylmethyl)-8-methoxy-3-aza-bicyclo[3.2.1]oct-8-yl]-benzamide;

N-{3-[3-(4-Fluoro-benzyl)-8-methoxy-3-aza-bicyclo[3.2.1]oct-8-yl]-phenyl}-methanesulfonamide;

3-[8-Methoxy-3-(4-pyrrolidin-1-yl-benzyl)-3-aza-bicyclo[3.2.1]oct-8-yl]-benzamide;

3-[8-Methoxy-3-(3-methyl-benzo[b]thiophen-2-ylmethyl)-3-aza-bicyclo[3.2.1]oct-8-yl]-benzamide;

3-[3-(2-Hydroxy-1,2,3,4-tetrahydro-naphthalen-2-ylmethyl)-8-methoxy-3-aza-bicyclo[3.2.1]oct-8-yl]-benzamide;

3-[3-(1-Hydroxy-3-phenyl-cyclobutylmethyl)-8-methoxy-3-aza-bicyclo[3.2.1]oct-8-yl]-benzamide;

N-{3-[3-(2-Ethyl-hexyl)-8-methoxy-3-aza-bicyclo[3.2.1]oct-8-yl]-phenyl}-methanesulfonamide;

N-[3-(8-Methoxy-3-octyl-3-aza-bicyclo[3.2.1]oct-8-yl)-phenyl]-methanesulfonamide;

2-Methoxy-ethanesulfonic acid [3-(3-hexyl-8-hydroxy-3-aza-bicyclo[3.2.1]oct-8-yl)-phenyl]-amide;

3-(3-Biphenyl-4-ylmethyl-8-methoxy-3-aza-bicyclo[3.2.1]oct-8-yl)-benzamide;

N-{3-[3-(2-Hydroxy-indan-2-ylmethyl)-3-aza-bicyclo[3.2.1]oct-8-yl]-phenyl}-methanesulfonamide;

N-{3-[8-Methoxy-3-(4-methoxy-benzyl)-3-aza-bicyclo[3.2.1]oct-8-yl]-phenyl}-methanesulfonamide;

2-Methoxy-ethanesulfonic acid [3-(8-hydroxy-3-pyridin-3-ylmethyl-3-aza-bicyclo[3.2.1]oct-8-yl)-phenyl]-amide;

3-[8-Methoxy-3-(3-trifluoromethoxy-benzyl)-3-aza-bicyclo[3.2.1]oct-8-yl]-benzamide;

N-{3-[3-(4-Chloro-benzyl)-8-methoxy-3-aza-bicyclo[3.2.1]oct-8-yl]-phenyl}-methanesulfonamide;

2-Methoxy-ethanesulfonic acid [3-(8-hydroxy-3-thiophen-3-ylmethyl-3-aza-bicyclo[3.2.1]oct-8-yl)-phenyl]-amide;

2-Methoxy-ethanesulfonic acid [3-(3-cyclohexylmethyl-8-hydroxy-3-aza-bicyclo[3.2.1]oct-8-yl)-phenyl]-amide;

N-(3-{8-Hydroxy-3-[3-(1-hydroxy-cyclohexyl)-propyl]-3-aza-bicyclo[3.2.1]oct-8-yl}-phenyl)-methanesulfonamide;

3-[3-(9H-Fluoren-2-ylmethyl)-8-methoxy-3-aza-bicyclo[3.2.1]oct-8-yl]-benzamide;

N-{3-[3-(1H-Indol-3-ylmethyl)-8-methoxy-3-aza-bicyclo[3.2.1]oct-8-yl]-phenyl}-methanesulfonamide;

N-[3-(3-Benzofuran-2-ylmethyl-8-methoxy-3-aza-bicyclo[3.2.1]oct-8-yl)-phenyl]-methanesulfonamide;

N-{3-[3-(2-Hydroxy-1,2,3,4-tetrahydro-naphthalen-2-ylmethyl)-3-aza-bicyclo[3.2.1]oct-8-yl]-phenyl}-methanesulfonamide;

3-[8-Methoxy-3-(3-phenoxy-benzyl)-3-aza-bicyclo[3.2.1]oct-8-yl]-benzamide;

N-{3-[8-Hydroxy-3-(2-hydroxy-indan-2-ylmethyl)-3-aza-bicyclo[3.2.1]oct-8-yl]-phenyl}-methanesulfonamide;

3-[3-(4-Dimethylamino-naphthalen-1-ylmethyl)-8-methoxy-3-aza-bicyclo[3.2.1]oct-8-yl]-benzamide;

2-Methoxy-ethanesulfonic acid [3-(8-hydroxy-3-phenethyl-3-aza-bicyclo[3.2.1]oct-8-yl)-phenyl]-amide;

N-[3-(8-Methoxy-3-naphthalen-1-ylmethyl-3-aza-bicyclo[3.2.1]oct-8-yl)-phenyl]-methanesulfonamide;

N-[3-(8-Methoxy-3-naphthalen-2-ylmethyl-3-aza-bicyclo[3.2.1]oct-8-yl)-phenyl]-methanesulfonamide;

N-(3-{3-[3-(1-Hydroxy-cyclohexyl)-propyl]-8-methoxy-3-aza-bicyclo[3.2.1]oct-8-yl}-phenyl)-methanesulfonamide;

N-[3-(8-Methoxy-3-quinolin-4-ylmethyl-3-aza-bicyclo[3.2.1]oct-8-yl)-phenyl]-methanesulfonamide;

N-[3-(8-Methoxy-3-quinolin-3-ylmethyl-3-aza-bicyclo[3.2.1]oct-8-yl)-phenyl]-methanesulfonamide;

N-{3-[3-(4-Chloro-2-fluoro-benzyl)-8-methoxy-3-aza-bicyclo[3.2.1]oct-8-yl]-phenyl}-methanesulfonamide;

2-Methoxy-ethanesulfonic acid [3-(8-hydroxy-3-octyl-3-aza-bicyclo[3.2.1]oct-8-yl)-phenyl]-amide;

N-{3-[8-Methoxy-3-(1-methyl-1H-indol-3-ylmethyl)-3-aza-bicyclo[3.2.1]oct-8-yl]-phenyl}-methanesulfonamide;

2-Methoxy-ethanesulfonic acid {3-[8-hydroxy-3-(3-phenyl-prop-2-ynyl)-3-aza-bicyclo[3.2.1]oct-8-yl]-phenyl}-amide;

N-{3-[8-Hydroxy-3-(2-hydroxy-1,2,3,4-tetrahydro-naphthalen-2-ylmethyl)-3-aza-bicyclo[3.2.1]oct-8-yl]-phenyl}-methanesulfonamide;

N-{3-[3-(2-Hydroxy-indan-2-ylmethyl)-8-methoxy-3-aza-bicyclo[3.2.1]oct-8-yl]-phenyl}-methanesulfonamide;

2-Methoxy-ethanesulfonic acid {3-[8-hydroxy-3-(3-phenyl-propyl)-3-aza-bicyclo[3.2.1]oct-8-yl]-phenyl}-amide;

2-Methoxy-ethanesulfonic acid {3-[3-(4-chloro-benzyl)-8-hydroxy-3-aza-bicyclo[3.2.1]oct-8-yl]-phenyl}-amide;

N-{3-[3-(4-Hydroxy-naphthalen-1-ylmethyl)-8-methoxy-3-aza-bicyclo[3.2.1]oct-8-yl]-phenyl}-methanesulfonamide;

2-Methoxy-ethanesulfonic acid {3-[8-hydroxy-3-(1H-indol-3-ylmethyl)-3-aza-bicyclo[3.2.1]oct-8-yl]-phenyl}-amide;

N-{3-[8-Methoxy-3-(4-pyrrolidin-1-yl-benzyl)-3-aza-bicyclo[3.2.1]oct-8-yl]-phenyl}-methanesulfonamide;

N-{3-[8-Methoxy-3-(3-methyl-benzo[b]thiophen-2-ylmethyl)-3-aza-bicyclo[3.2.1]oct-8-yl]-phenyl}-methanesulfonamide;

2-Methoxy-ethanesulfonic acid [3-(3-benzofuran-2-ylmethyl-8-hydroxy-3-aza-bicyclo[3.2.1]oct-8-yl)-phenyl]-amide;

N-{3-[3-(2-Hydroxy-1,2,3,4-tetrahydro-naphthalen-2-ylmethyl)-8-methoxy-3-aza-bicyclo[3.2.1]oct-8-yl]-phenyl}-methanesulfonamide;

~~2,2,2-Trifluoro-N-{3-[3-(2-hydroxy-indan-2-ylmethyl)-8-methoxy-3-aza-bicyclo[3.2.1]oct-8-yl]-phenyl}-acetamide;~~

N-[3-(3-Biphenyl-4-ylmethyl-8-methoxy-3-aza-bicyclo[3.2.1]oct-8-yl)-phenyl]-methanesulfonamide;

2-Methoxy-ethanesulfonic acid [3-(8-hydroxy-3-naphthalen-2-ylmethyl-3-aza-bicyclo[3.2.1]oct-8-yl)-phenyl]-amide;

2-Methoxy-ethanesulfonic acid [3-(8-hydroxy-3-naphthalen-1-ylmethyl-3-aza-bicyclo[3.2.1]oct-8-yl)-phenyl]-amide;

2-Methoxy-ethanesulfonic acid (3-{8-hydroxy-3-[3-(1-hydroxy-cyclohexyl)-propyl]-3-aza-bicyclo[3.2.1]oct-8-yl}-phenyl)-amide;

2-Methoxy-ethanesulfonic acid [3-(8-hydroxy-3-quinolin-4-ylmethyl-3-aza-bicyclo[3.2.1]oct-8-yl)-phenyl]-amide;

2-Methoxy-ethanesulfonic acid [3-(8-hydroxy-3-quinolin-3-ylmethyl-3-aza-bicyclo[3.2.1]oct-8-yl)-phenyl]-amide;

2-Methoxy-ethanesulfonic acid {3-[8-hydroxy-3-(1-methyl-1H-indol-3-ylmethyl)-3-aza-bicyclo[3.2.1]oct-8-yl]-phenyl}-amide;

N-{3-[8-Methoxy-3-(3-trifluoromethoxy-benzyl)-3-aza-bicyclo[3.2.1]oct-8-yl]-phenyl}-methanesulfonamide;

2-Methoxy-ethanesulfonic acid{3-[3-(2-hydroxy-1,2,3,4-tetrahydro-naphthalen-2-ylmethyl)-3-aza-bicyclo[3.2.1]oct-8-yl]-phenyl}-amide;

2-Methoxy-ethanesulfonic acid {3-[8-hydroxy-3-(2-hydroxy-indan-2-ylmethyl)-3-aza-bicyclo[3.2.1]oct-8-yl]-phenyl}-amide;

N-{3-[3-(9H-Fluoren-2-ylmethyl)-8-methoxy-3-aza-bicyclo[3.2.1]oct-8-yl]-phenyl}-methanesulfonamide;

2-Methoxy-ethanesulfonic acid {3-[8-hydroxy-3-(2-phenethyloxy-ethyl)-3-aza-bicyclo[3.2.1]oct-8-yl]-phenyl}-amide;

N-{3-[8-Methoxy-3-(3-phenoxy-benzyl)-3-aza-bicyclo[3.2.1]oct-8-yl]-phenyl}-methanesulfonamide;

N-{3-[3-(4-Dimethylamino-naphthalen-1-ylmethyl)-8-methoxy-3-aza-bicyclo[3.2.1]oct-8-yl]-phenyl}-methanesulfonamide;

2-Methoxy-ethanesulfonic acid {3-[8-hydroxy-3-(4-hydroxy-naphthalen-1-ylmethyl)-3-aza-bicyclo[3.2.1]oct-8-yl]-phenyl}-amide;

2-Methoxy-ethanesulfonic acid {3-[8-hydroxy-3-(4-pyrrolidin-1-yl-benzyl)-3-aza-bicyclo[3.2.1]oct-8-yl]-phenyl}-amide;

2-Methoxy-ethanesulfonic acid {3-[8-hydroxy-3-(3-methyl-benzo[b]thiophen-2-ylmethyl)-3-aza-bicyclo[3.2.1]oct-8-yl]-phenyl}-amide;

2-Methoxy-ethanesulfonic acid {3-[3-(2-hydroxy-1,2,3,4-tetrahydro-naphthalen-2-ylmethyl)-8-hydroxy-3-aza-bicyclo[3.2.1]oct-8-yl]-phenyl}-amide;

2-Methoxy-ethanesulfonic acid {3-[3-(2-hydroxy-indan-2-ylmethyl)-8-methoxy-3-aza-bicyclo[3.2.1]oct-8-yl]-phenyl}-amide;

2-Methoxy-ethanesulfonic acid [3-(3-biphenyl-4-ylmethyl-8-hydroxy-3-aza-bicyclo[3.2.1]oct-8-yl)-phenyl]-amide;

2-Methoxy-ethanesulfonic acid {3-[3-(2-hydroxy-1,2,3,4-tetrahydro-naphthalen-2-ylmethyl)-8-methoxy-3-aza-bicyclo[3.2.1]oct-8-yl]-phenyl}-amide;

2-Methoxy-ethanesulfonic acid {3-[3-(9H-fluoren-2-ylmethyl)-8-hydroxy-3-aza-bicyclo[3.2.1]oct-8-yl]-phenyl}-amide;

2-Methoxy-ethanesulfonic acid {3-[8-hydroxy-3-(3-phenoxy-benzyl)-3-aza-bicyclo[3.2.1]oct-8-yl]-phenyl}-amide;

2-Methoxy-ethanesulfonic acid {3-[3-(4-dimethylamino-naphthalen-1-ylmethyl)-8-hydroxy-3-aza-bicyclo[3.2.1]oct-8-yl]-phenyl}-amide;

3-(3-Cyclopropylmethyl-8-hydroxy-3-aza-bicyclo[3.2.1]oct-8-yl)-phenol;

3-{3-[3-(1-Hydroxy-cyclohexyl)-propyl]-3-aza-bicyclo[3.2.1]oct-8-yl}-phenol; and

3-(3-Cyclohexyl-propyl)-8-(3-hydroxy-phenyl)-3-aza-bicyclo[3.2.1]octan-8-ol;

or pharmaceutically acceptable salts thereof.

11(withdrawn). A pharmaceutical composition comprising an effective amount of a compound according to claim 1 in combination with a pharmaceutically acceptable carrier, excipient or additive.

12(withdrawn). A method of treating in a mammal, in need thereof, a disease state, disorder or condition selected from the group consisting of irritable bowel syndrome, constipation, nausea, vomiting, pruritic dermatoses, psoriasis; eczema; an insect bite; eating disorders, depression, anxiety, schizophrenia; drug addiction, an opioid overdose, sexual dysfunction, stroke, head trauma, traumatic brain injury, spinal damage, Parkinson's disease, Alzheimer's disease, age-related cognitive decline and Attention Deficit and Hyperactivity Disorder, said method comprising

administering to said mammal an amount of a compound according to claim 1 effective in treating said disease state, disorder or condition.

13-15 (cancelled).